Market factor

Product launches, trial results, and approvals

Impact tier: 4 — Stock and sector specific
Category: Corporate actions and stock-specific events
Watch: FDA PDUFA dates; clinical readouts; product events
Frequency: event
Effect lasts: days

Product launches, trial results, and approvals. Binary for biotech; for consumer tech the reaction is to pre-orders and reviews.

What to watch: FDA PDUFA dates; clinical readouts; product events. It arrives event, and the effect typically lasts days.

It sits in tier 4 — Stock and sector specific: Moves one company or one group, not the market. Any factor here becomes tier one if it gets large enough — a bank failure and a pandemic both started as somebody's sector news.

Primary source — fda.gov ↗

Its neighbourhood

Everything this entry connects to directly. Click any point to follow it.

Sectors it moves most

Healthcare and pharmaceuticals$4.6T
Technology and media$14.5T

Trends tracked by this

GLP-1 obesity and metabolic drugsCompounding now. Evidence is visible in company results and data.
Preventive, personalised, and consumer-driven medicineCompounding now. Evidence is visible in company results and data.
Longevity biotech and cell/gene therapyReal but not yet at scale. The effects described are expected rather than observed.
Women's health and the menopause marketCompounding now. Evidence is visible in company results and data.
Mental health demand and the therapy shortageCompounding now. Evidence is visible in company results and data.
Spatial computing, AR, and brain-computer interfacesReal but not yet at scale. The effects described are expected rather than observed.

Also in Corporate actions and stock-specific events

Individual earnings reports and guidanceTier 4
Pre-announcements and profit warningsTier 4
Mergers and acquisitionsTier 4
IPOs, lockup expirations, and secondariesTier 4
Share issuance and dilutionTier 4
Insider buying and sellingTier 4
Activist investors and 13D filingsTier 4
13F holdings disclosuresTier 4
Analyst upgrades, downgrades, and price targetsTier 4
Short-seller reports and accounting questionsTier 4
Management and board changesTier 4
Litigation, settlements, and product liabilityTier 4
Corporate credit rating changesTier 4
Dividend cuts, initiations, and special dividendsTier 4
Stock splitsTier 4
Index inclusion and deletionTier 4
IPO window and public-market shrinkageTier 3
FDA approvals and PDUFA datesTier 4
Private equity exit backlog and marksTier 3